BioAge Labs, Inc.

Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr

Another company joined the burgeoning obesity therapy space on 28 January, as Versant Ventures-backed Helicore Biopharma unveiled a $65m series A financing and initial plans to take a first-in-class

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’

In a big setback for BioAge Labs, the company is discontinuing a Phase II trial of its lead drug azelaprag for obesity after cases of liver transaminitis were observed in some patients taking the drug